ASX closes flat, as monster miners move up
The ASX 200 flattened out to close a Thursday that saw Chemist Warehouse land on the bourse via Sigma. Meanwhile, mining stocks led the sectors.
Stockhead
Guy on Rocks: AZ9
Guy Le Page looks at Mongolian-based metals explorer Asian Battery Metals and some eye-opening polymetallics with grade and scale.
VHM lays out growth strategy at Goschen
A fresh development strategy for the Goschen project has ensured a low-risk pathway to production for the asset.
OBM eyes multi-year lift to Riverina mine life
Ora Banda Mining’s gold drilling has defined a multi-year extension to the Riverina Underground mine life and made the Little Gem greenfields discovery.
More Stories
OZM’s high-grade gold hits excites punters
OzAurum’s high-grade drill hits at the Mulgabbie North project have identified a new zone that outlines its potential to host significant mineralisation.
Caprice targets maiden gold resource
Caprice has recommenced drilling at its promising Island gold project, which hosts historic workings just 12km from Ramelius’ Cue mine.
OZM hits high-grade gold at Mulgabbie North
Drill hits of up to 4m at 14.17g/t gold have led to OzAurum identifying a new high-grade target at its Mulgabbie North gold project.
Cash backs Indiana’s golden opportunity
Indiana Resources is a rare junior with massive cash backing, but its South Australian gold prospects could be the real value driver.
Paradigm eyes $110m raise with loyalty offer
Paradigm Biopharmaceuticals has launched loyalty options and piggyback options offers which could potentially raise more than $110 million.
How major commodities fared in 2024
Gold outshined the chasing pack as only a handful of commodities sailed through choppy economic waters unscathed in a tumultuous 2024.
Shares dive on Trump’s tariffs
The ASX has crashed today on Trump’s tariffs. Meanwhile oil has risen, crypto has absolutely face-planted and Novonix is up on an anti-China dumping win.
PAR picks Advanced Clinical for key trial
Paradigm Biopharmaceuticals has selected Advanced Clinical as the preferred clinical research organisation for the phase III trial for PARA_OA_012.
AAR moves to acquire MXR
Astral Resources’ takeover offer values Maximus Resources at ~$31m and will provide more flexible future development of existing gold resources.
Semiconductor veteran joins the AI1 board
Kevin Crofton joins Fraser Palamara on Stockhead TV to discuss why he joined the Adisyn team.
Original URL: https://www.themercury.com.au/business/stockhead/page/23